What Kolinpharma does

Kolinpharma S.p.A. is an Italian nutraceutical company founded in 2013 and publicly listed on AIM Italia (Borsa Italiana's SME market) since March 2018, operating under parent IGEA Holding S.p.A. The company develops and commercializes patented food supplements across five therapeutic verticals: gastroenterological (Prointex), neurological (Declinex, Kymax), uro-gynecological (KIPFeR, Almetax, Ivuxur, Miledix, Xinprox), osteo-articular (Dolatrox, Milesax, Xinepa, Doltendix), and immunological (KIP IMMUNO). The company holds 51 patents across Italy, USA, Israel, Europe, and China, with US patents valid through 2035, covering proprietary formulations and licensed technology such as IHAT (Iron Hydroxide Adipate Tartrate) from Nemysis LTD for the KIPFeR iron supplement.

The business model is product sales through a multi-channel distribution network: a 42-strong direct medical-scientific sales force (IMS) targeting Italian specialists in orthopedics, gynecology, neurology, and gastroenterology; traditional pharmacy and para-pharmacy retail; a proprietary e-commerce platform launched in 2021; and international distribution partnerships, most notably with ASTAREAL AB for China, Hong Kong, Macao, and Taiwan since October 2022. The company manufactures through third-party production sites audited for ISO 9001, ISO 22000, and ISO 37001 compliance, and holds B Corp, Kosher, Halal, Doping Free, and Gluten Free certifications. Rita Paola Petrelli is the founder and President of the Board.

Revenue growth has been consistently above 15% CAGR over multiple measurement periods, peaking at 52.71% (2016-2019) and most recently measured at 24.02% (2020-2023), supporting six consecutive years on Il Sole 24 Ore's Leader della Crescita ranking and 1st place in Europe in Health Care & Life Sciences in the Financial Times Europe's Long-term Growth Champions 2026. Geographic expansion has progressed from Italy to Germany, France, Spain, Poland, Israel, USA, China, Hong Kong, and Taiwan, primarily through patent validation and distribution partnerships rather than owned subsidiaries.

Name

Kolinpharma

Legal name

KOLINPHARMA S.p.A

Website

https://kolinpharma.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Kolinpharma S.p.A. is an Italian publicly-listed nutraceutical company that develops and sells patented food supplements across five therapeutic verticals (gastroenterological, neurological, uro-gynecological, osteo-articular, immunological) through Italian pharmacy channels, a proprietary medical sales force, e-commerce, and international distribution partnerships.

Ownership category

akta.pro rank

Product category

Nutraceutical Supplements

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

Keywords

• Nutraceutical supplements
• Patented dietary supplements
• Clinical research services
• Pharmaceutical manufacturing
• Wellness food supplements

Headquarters

HQ city

Lainate

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Infrastructure

Revenue model

1. Nutraceutical product sales: Kolinpharma generates revenue through the sale of patented nutraceutical products across multiple therapeutic lines (gastrointestinal, neurological, uro-gynecological, osteo-articular, immunological). Products are sold through pharmacies, para-pharmacies, and direct-to-consumer e-commerce.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Kolinpharma S.p.A. develops, manufactures and markets patented nutraceutical supplements organized into five therapeutic lines: gastroenterological (Prointex®), neurological (Kymax®, Declinex®), uro-gynecological (KIPFeR®, Almetax®, Ivuxur®, Miledix®, Xinprox®), osteo-articular (Dolatrox®, Milesax®, Xinepa®, Doltendix®) and immunological (KIP® IMMUNO). Products are sold to end consumers through Italian pharmacies and para-pharmacies supported by a medical-scientific representative (IMS) network, plus the company's own e-commerce platform, with international distribution via partnerships.

Product overview

Kolinpharma S.p.A. is a nutraceutical company organized into five product lines: Gastroenterological (Prointex®), Neurological (Kymax®, Declinex®), Uro-Gynecological (KIPFeR®, Almetax®, Almetax Easy®, Ivuxur®, Miledix®, Xinprox®), Osteo-Articular (Dolatrox®, Milesax®, Xinepa®, Doltendix®), and Immunological (KIP® IMMUNO). The company also offers wellness products (KIP® KIT, KIP® FLU). Products are distributed through pharmacies, parapharmacies, e-commerce, and international distribution partners. Kolinpharma operates as a certified B Corp and Benefit Company with 51 patents across Italy, USA, Israel, and European countries.

Differentiator

Problem solved

Functional benefit

Brands

• Prointex: Innovative nutraceutical for gastrointestinal health, launching the new gastroenterological line in 2026
• Kymax
• Declinex
• KIPFeR
• Dolatrox
• Milesax
• Xinepa
• Almetax
• Ivuxur
• Miledix
• Xinprox
• Doltendix
• KIP IMMUNO

Products and services

• Prointex® Patented nutraceutical for gastrointestinal well-being combining resveratrol, saffron extract, B vitamins, vitamin D, zinc, calcium and 5 probiotics to support the gut-brain axis, digestive function and psychological well-being. Targeted at consumers suffering from functional gastrointestinal disorders such as IBS, sold through pharmacies, para-pharmacies and e-commerce.
• Kymax® Patented neuroscience line supplement combining DHA, green tea extract, alpha lipoic acid, saffron, vitamin E, prebiotic/probiotic and B vitamins to support nervous system function, mood maintenance and cerebral function. Marketed to consumers seeking neurological wellness, available in pharmacies and online.
• Declinex® Nutraceutical for neurodegenerative disease support combining green tea extract, Epigallocatechingallate, saffron, Veri-te trans-resveratrol, Cognizin citicoline, zinc and micronutrients to promote mental well-being and mood improvement. Sold through pharmacy and para-pharmacy channels and e-commerce.
• KIPFeR® Iron supplement based on Iron Hydroxide Adipate Tartrate (IHAT™) — an innovative nanoparticle iron source approved by EFSA as NOVEL FOOD and licensed from Nemysis LTD. Designed for consumers with iron deficiency and anemia, claimed to be well tolerated without negative impact on intestinal microbiota.
• Almetax® Patented food supplement for uro-gynecological wellness targeting menopausal symptoms. Available in tablet form, protected by a US patent obtained November 2021. Sold through pharmacies, para-pharmacies and e-commerce.
• Almetax Easy® Orosoluble (easy-dissolve) formulation variant of Almetax® designed for easier patient compliance. Targeted at the same uro-gynecological/menopausal wellness segment as the tablet form.
• Ivuxur® Bustine Sachet-form food supplement for urinary tract well-being, part of Kolinpharma's uro-gynecological line. Protected by European patent obtained November 2021 valid in Germany, France and Italy.
• Ivuxur® Compresse Innovative three-layer tablet food supplement for urinary tract well-being, expanding the Ivuxur range into a new dosage format to address additional patient targets.
• Miledix® Food supplement for women's menstrual cycle wellness, designed to alleviate premenstrual syndrome, dysmenorrhea and related mood swings/irritability. Contains saffron, resveratrol, magnesium bisglycinate chelate and L-tryptophan. Protected by Italian patent obtained December 2020.
• Xinprox® Food supplement for prostate wellness containing pollen extract, quercetin, alpha lipoic acid and L-tryptophan. Holds 7 patents in Italy, 6 in USA, 1 in Israel and 32 in European countries (first patent obtained December 2022).
• Dolatrox® Anti-inflammatory food supplement for osteo-articular wellness. Also available as a medical device (Dolatrox® hcc). Protected by 4th US patent obtained March 2020, valid until 2035.
• Milesax® Blockbuster nutraceutical combining magnesium bisglycinate chelate, Boswellia serrata and L-tryptophan to support nervous system function, muscle functionality, contractures, muscle relaxation and mood. Protected by 5th US patent obtained October 2020 (valid until 2035) and additional European patents.
• Xinepa® Nutraceutical for neuropathies and neuropathic pain with double Italian patent. Available in tablet and orosoluble forms. First Israeli patent obtained April 2020 (fifth patent outside Italy) with additional formulation and process patents in 12 European countries.
• Xinepa Easy® Orosoluble (easy-dissolve) formulation variant of Xinepa® designed for easier patient compliance in the neuropathy/neuropathic pain segment.
• Doltendix® Tendon-wellness food supplement in Kolinpharma's KipBlue (orthopedic-physiatric) line, formulated with bioactive collagen peptides, astaxanthin, trans-resveratrol and vitamin C. First Italian patent obtained January 2022; first China patent obtained May 2024.
• KIP® IMMUNO Immunological line food supplement supporting immune system function and natural defenses, part of Kolinpharma's five core therapeutic lines. Sold through pharmacies, para-pharmacies and e-commerce.
• KIP® FLU Food supplement supporting immune system function and natural defense. Sold as a standalone product and as part of the KIP® KIT welfare package for employee wellness programs.
• KIP® KIT Welfare package bundling KIP® FLU immune supplement with hand sanitizer gel and washable/reusable mask, marketed for corporate employee wellness programs. Used by enterprise customers such as Mecar.

Quantifiable outcome

• CAGR revenue growth of 24.02% (2020-2023)
• +4 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• La Neurologia Italiana / MeP EdizionicoreStrategic or Co-development Partner · 18 February 2026Partnership renewal for medical education (CME), research and development sharing, and scientific dialogue between biochemistry innovation and clinical application.
• RCS MediaGroup / Corriere SalutecoreGTM or Marketing Partner · 2 February 2026Editorial collaboration with Corriere della Sera health supplement for nutraceutical awareness and scientific content dissemination in Italian market.
• Nemysis LimitedcoreStrategic or Co-development Partner · 14 November 2025Kolinpharma, through parent company IGEA Holding S.p.A., invested in Nemysis via a Subscription Agreement to fund commercialization of IHAT oral iron supplement and enzymatic therapy Endoprotease 40. This follows the earlier KIPFeR product launch agreement.
• Nemysis LTDcoreTechnology or Integration · 10 January 2024Product licensing agreement for KIPFeR, an iron supplement based on IHAT (Idrossido di Ferro Adipato Tartrato) - innovative nanoparticle iron source approved by EFSA.
• ASTAREAL ABcoreChannel Partner/ Reseller/ Distributor · 25 October 2022Three-year distribution agreement for China Continental, Hong Kong, Macao, Taiwan with Cross Border E-commerce setup, digital marketing and social media support through Shanghai team.
• Università La Sapienza di RomaminorStrategic or Co-development Partner · 23 January 2019Collaboration for Master of II Level 'The key manager in nutraceutical and cosmeceutical company' - training future managers with multidisciplinary competencies.
• Hoffmann & Eitle ItaliaminorImplementation/ SI/ Consulting Partner · 2 January 2018Patent legal services - one of Europe's largest IP law firms with professionals from 10+ nations specializing in patents, utility models, and industrial design protection.
• Bomi GroupminorOthers · 1 January 2017Storage and logistics partner since 2017 - temperature-controlled warehousing and transport services using partner-owned vehicles. Bomi Group is AIM-listed.
• KIPTOGO SchoolminorOthersCorporate social responsibility project supporting education rights for children in Kouni village, Togo - providing school materials, uniforms, and building school infrastructure.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Recordati S.p.A. Largest listed Italian pharmaceutical group with established specialty pharma and consumer health operations across multiple therapeutic areas. Overlaps with Kolinpharma in uro-gynecological and pain categories but at vastly larger scale and broader portfolio.
• Nestlé Health Science: Global consumer-health subsidiary of Nestlé operating in vitamins, minerals, supplements and medical nutrition across categories including gastrointestinal, women's health and active aging that overlap with Kolinpharma's therapeutic lines.
• Dompé Farmaceutici S.p.A. Italian biopharmaceutical company with primary care, specialty and consumer health divisions including nutraceutical lines. Comparable on Italian HQ, R&D intensity and overlap in women's health and pain/inflammation categories.
• Zambon S.p.A. Italian multinational pharmaceutical and fine chemicals group with branded specialty and consumer health products across respiratory, pain and women's health. Comparable as a larger Italian incumbent with overlapping condition-specific portfolios.
• Perrigo Company plc: Global consumer self-care company producing store-brand and branded OTC pharmaceuticals, vitamins and dietary supplements. Comparable as a much larger incumbent operating in the same nutraceutical category across multiple geographies.
• Chiesi Farmaceutici S.p.A. Private Italian multinational pharmaceutical company operating in specialty care (respiratory, neonatology, rare disease) with growing consumer health presence. Comparable as an established Italian life sciences player investing in evidence-based specialty categories.

Direct peers

• Pharmanutra S.p.A. Italian nutraceutical company also listed on AIM Italia, focused on condition-specific nutritional supplements with patented formulations sold through pharmacy channels. Closest direct comparable on geography, scale, distribution model and category focus.
• Molteni Farmaceutici: Italian specialty pharmaceutical company with branded nutraceutical and prescription franchises sold through specialist and pharmacy channels. Comparable in mid-cap Italian footprint and therapeutic-area focus (pain, gynecology, neurology).
• Newron Pharmaceuticals S.p.A. Italy-based, publicly traded biopharmaceutical company focused on CNS disorders, comparable to Kolinpharma in Italian listed-pharma status and in targeting neurological/neurodegenerative conditions through patented science-based products.
• Abiogen Pharma S.p.A. Italian specialty pharmaceutical company with branded prescription and consumer health franchises in bone, joint and women's health categories. Direct overlap with Kolinpharma's osteo-articular (Dolatrox, Milesax, Doltendix) and uro-gynecological (Almetax, Miledix) lines.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/kolinpharma
• Facebookfacebook.com/1467632016830074
• LinkedInlinkedin.com/company/kolinpharma

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kolinpharma